In the Claims

1. (Currently amended) A conjugate comprising a first sequence and a second sequence, wherein the first sequence comprises a protein which binds to an antigen presenting cell (APC), ~~or a polynucleotide encoding therefor,~~ and wherein the second sequence comprises a Notch ligand or a fragment thereof which retains Notch signalling activity ~~protein which modulates a T cell signalling pathway, or a polynucleotide coding therefor~~.

2. (Original) The conjugate according to claim 1, wherein the conjugate is a fusion protein.

3-7. (Cancelled)

8. (Currently amended) The conjugate according to ~~claim 7~~ claim 1, wherein the second sequence is ~~derived~~ from Notch ligands Delta or Serrate~~, or a polynucleotide coding therefor~~.

9-17. (Cancelled)

18. (Currently amended) The conjugate according to ~~claim 16~~ claim 1, wherein the first sequence is a protein which binds to an MHC class II molecule.

19. (Original) The conjugate according to claim 1, wherein the first sequence is a superantigen, or is derived therefrom.

20. (Original) The conjugate according to claim 19, wherein the superantigen is of bacterial or viral origin.

21. (Original) The conjugate according to claim 19, wherein the first sequence comprises the MHC class II binding domain of the superantigen.

22. (Original) The conjugate according to claim 19, wherein the superantigen is a Staphylococcal enterotoxin (SE) selected from the group consisting of SEA, SEB, SEC, SED, SEE and SEH.

23. (Original) The conjugate according to claim 21, wherein the superantigen is Toxic Shock syndrome toxins (TSST-1).

24. (Original) The conjugate according to claim 19, wherein the superantigen is a Streptococcal enterotoxin (SPE) selected from the group consisting of SPEA, SPEC and SSA.

25-28. (Cancelled)

29. (Currently amended) A conjugate prepared by ~~the method of claim 28.~~

(a) transforming a host cell with an expression vector comprising a polynucleotide sequence encoding the conjugate of claim 1; and

(b) culturing the host cell under conditions which provide for expression of the conjugate.

30. (Withdrawn) A method of targeting a protein for Notch signalling modulation, or a polynucleotide coding therefor, to an APC comprising exposing the APC to the conjugate according to claim 1.

31. (Original) A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

32. (Withdrawn) A method of preventing or treating a disease or infection a subject in need thereof, comprising administering the conjugate according to claim 1 to the subject.

33. (Withdrawn) The method according to claim 32, wherein the disease is a T-cell mediated disease.

34. (New) A conjugate comprising a first sequence and a second sequence, wherein the first sequence comprises a protein which binds to an antigen presenting cell (APC), and wherein the second sequence comprises a Notch ligand DSL domain and at least one EGF-like domain and wherein the second sequence retains Notch signalling activity.

35. (New) The conjugate according to claim 34, wherein the first sequence comprises a protein which binds to an APC surface molecule, wherein the APC surface molecule is selected from the group consisting of an MHC class II molecule, CD205 (DEC205), CD204, CD14, CD206, TLRs, Langerin (CD207), DC-SIGN (CD209), CD32, CD68, CD83, CD33, CD54 and BDCA-2,3,4.